Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis.
Cerebral palsy
MgSO4
magnesium sulphate
meta-analysis
neuroprotection
preterm delivery
systematic review
trial sequential analysis
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
accepted:
18
03
2020
pubmed:
3
4
2020
medline:
1
9
2020
entrez:
3
4
2020
Statut:
ppublish
Résumé
Ordinary meta-analyses indicate that magnesium sulphate (MgSO To assess the possible fetal neuroprotective effect of MgSO We searched MEDLINE, Embase, Cochrane and ClinicalTrials.gov on 8 October 2019. The search strategy clustered terms describing the MgSO RCTs. Two reviewers extracted the data. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using fixed-effects models. A TSA was applied to the primary outcome, CP. The quality of the evidence was assessed using GRADE. The protocol was registered in PROSPERO (registration: CRD42019151441). We identified six eligible trials (5917 women). MgSO This systematic review with meta-analysis and TSA shows conclusively that MgSO Antenatal magnesium sulphate decreases the risk of cerebral palsy in children born preterm.
Sections du résumé
BACKGROUND
Ordinary meta-analyses indicate that magnesium sulphate (MgSO
OBJECTIVES
To assess the possible fetal neuroprotective effect of MgSO
SEARCH STRATEGY
We searched MEDLINE, Embase, Cochrane and ClinicalTrials.gov on 8 October 2019. The search strategy clustered terms describing the MgSO
SELECTION CRITERIA
RCTs.
DATA COLLECTION AND ANALYSIS
Two reviewers extracted the data. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using fixed-effects models. A TSA was applied to the primary outcome, CP. The quality of the evidence was assessed using GRADE. The protocol was registered in PROSPERO (registration: CRD42019151441).
MAIN RESULTS
We identified six eligible trials (5917 women). MgSO
CONCLUSIONS
This systematic review with meta-analysis and TSA shows conclusively that MgSO
TWEETABLE ABSTRACT
Antenatal magnesium sulphate decreases the risk of cerebral palsy in children born preterm.
Identifiants
pubmed: 32237069
doi: 10.1111/1471-0528.16238
doi:
Substances chimiques
Neuroprotective Agents
0
Magnesium Sulfate
7487-88-9
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1180-1188Subventions
Organisme : Elsass Foundation
ID : 19-3-0457
Pays : International
Informations de copyright
© 2020 Royal College of Obstetricians and Gynaecologists.
Références
LiuL, JohnsonHL, CousensS, PerinJ, ScottS, LawnJE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet2012;379:2151-61.
SaigalS, DoyleLW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet2008;371:261-9.
GariteTJ, CombsCA. Obstetric interventions beneficial to prematurely delivering newborn babies: antenatal corticostetroids, progesterone, magnesium sulfate. Clin Perinatol2012;39:33-45.
WolfHT, HegaardHK, GreisenG, HuusomL, HedegaardM. Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies. J Obstet Gynaecol2012;32:135-40.
DoyleLW, CrowtherCA, MiddletonP, MarretS, RouseD. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane database Syst Rev2009:CD004661.
CostantineMM, WeinerSJ, KennedyEunice. Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstet Gynecol2009;114(2 Pt 1):354-64.
WolfHT, BrokJ, HenriksenTB, GreisenG, SalvigJD, PrydsO, et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG2020 Apr 1; Epub ahead of print.
MoherD, LiberatiA, TetzlaffJ, AltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol2009;62:1006-12.
DuleyL, TMTFSC group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG2007;114:300-9.
van ʼtHooftJ, DuffyJMN, DalyM, WilliamsonPR, MeherS, ThomE, SaadeGR, AlfirevicZ, MolBWJ, KhanKS. A core outcome set for evaluation of interventions to prevent preterm birth. Obstet Gynecol2016;127:49-58.
HigginsJPT, ThomasJ, ChandlerJ, CumpstonM, LiT, PageMJWV. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. 2019.
BalshemH, HelfandM, SchünemannHJ, OxmanAD, KunzR, BrozekJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol2011;64:401-6.
HuusomLD, SecherNJ, PrydsO, WhitfieldK, GluudC, BrokJ. Antenatal magnesium sulphate may prevent cerebral palsy in preterm infants-but are we convinced? Evaluation of an apparently conclusive meta-analysis with trial sequential analysis. BJOG2011;118:1-5.
BrokJ, ThorlundK, WetterslevJ, GluudC. Apparently conclusive meta-analyses may be inconclusive-Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol2009;38:287-98.
BrokJ, ThorlundK, GluudC, WetterslevJ. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol2008;61:763-9.
RouseDJ, HirtzDG, ThomE, VarnerMW, SpongCY, MercerBM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med2008;359:895-905.
CrowtherCA, HillerJE, DoyleLW, HaslamRR, Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA2003;290:2669-76.
MittendorfR, DambrosiaJ, PrydePG, LeeK-S, GianopoulosJG, BesingerRE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol2002;186:1111-8.
MarretS, MarpeauL, Zupan-SimunekV, EurinD, LévêqueC, HellotM-F, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*. BJOG2007;114:310-8.
AlBalawiZ, McAlisterFA, ThorlundK, WongM, WetterslevJ. Random error in cardiovascular meta-analyses: how common are false positive and false negative results?Int J Cardiol2013;168:1102-7.
KosterTM, WetterslevJ, GluudC, JakobsenJC, KaufmannT, EckRJ, et al. Apparently conclusive meta-analyses on interventions in critical care may be inconclusive-a meta-epidemiological study. J Clin Epidemiol2019;114:1-10.
TurnerRM, BirdSM, HigginsJPT. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One2013;8:e59202.
EggerM, SmithGD, SterneJA. Meta-analysis: is moving the goal post the answer?Lancet (London, England)1998;351:1517.
WolfHT, HuusomL, WeberT, PiedvacheA, SchmidtS, NormanM, et al. Use of magnesium sulfate before 32 weeks of gestation: A European population-based cohort study. BMJ Open2017;7:e013952.
JayaramPM, MohanMK, FaridI, LindowS. Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. J Perinat Med2019;47:262-9.
KnightlyR, MilanSJ, HughesR, Knopp-SihotaJA, RoweBH, NormansellR, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane database Syst Rev2017;11:CD003898.
CrowtherCA, MiddletonPF, VoyseyM, AskieL, DuleyL, PrydePG, et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Med2017;14:e1002398.
CrowtherCA, MiddletonPF, WilkinsonD, AshwoodP, HaslamR, MAGENTA Study Group. Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol. BMC Pregnancy Childbirth2013;9:91.
VilchezG, DaiJ, LagosM, SokolRJ. Maternal side effects & fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. J Matern Fetal Neonatal Med2018;31:178-83.